ZA984633B - Treatment of schizophrenia and psychosis - Google Patents

Treatment of schizophrenia and psychosis

Info

Publication number
ZA984633B
ZA984633B ZA984633A ZA984633A ZA984633B ZA 984633 B ZA984633 B ZA 984633B ZA 984633 A ZA984633 A ZA 984633A ZA 984633 A ZA984633 A ZA 984633A ZA 984633 B ZA984633 B ZA 984633B
Authority
ZA
South Africa
Prior art keywords
psychosis
schizophrenia
treatment
diseases
methylpyridine
Prior art date
Application number
ZA984633A
Other languages
English (en)
Inventor
Frank Sams-Dodd
Jorn Arnt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA984633B publication Critical patent/ZA984633B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA984633A 1997-05-29 1998-05-29 Treatment of schizophrenia and psychosis ZA984633B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK62097 1997-05-29

Publications (1)

Publication Number Publication Date
ZA984633B true ZA984633B (en) 1998-12-11

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984633A ZA984633B (en) 1997-05-29 1998-05-29 Treatment of schizophrenia and psychosis

Country Status (10)

Country Link
US (1) US6297262B1 (xx)
EP (1) EP1014974B1 (xx)
JP (1) JP2002500651A (xx)
AT (1) ATE273007T1 (xx)
AU (1) AU7639598A (xx)
DE (1) DE69825605T2 (xx)
ES (1) ES2227836T3 (xx)
PT (1) PT1014974E (xx)
WO (1) WO1998053820A1 (xx)
ZA (1) ZA984633B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2854836B1 (en) 2012-06-05 2018-04-04 The Board of Trustees of The Leland Stanford Junior University Ncam peptide mimetic for use in treating major depression disorder
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3789039T2 (de) 1986-06-27 1994-06-09 Beecham Group Plc Verbrückte bicyclische N-heterocyclische Verbindungen.
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
KR100272614B1 (ko) 1992-08-31 2000-11-15 엠. 잭 오해니언 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
HU221729B1 (hu) * 1993-08-19 2002-12-28 Novo Nordisk A/S Tiadiazolil-piridin-származékok alkalmazása antipszichotikus gyógyszerek előállítására
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Also Published As

Publication number Publication date
JP2002500651A (ja) 2002-01-08
WO1998053820A1 (en) 1998-12-03
EP1014974A1 (en) 2000-07-05
DE69825605D1 (de) 2004-09-16
PT1014974E (pt) 2004-12-31
ATE273007T1 (de) 2004-08-15
US6297262B1 (en) 2001-10-02
EP1014974B1 (en) 2004-08-11
AU7639598A (en) 1998-12-30
DE69825605T2 (de) 2005-09-15
ES2227836T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
ZA984633B (en) Treatment of schizophrenia and psychosis
TW249226B (xx)
NO913765D0 (no) Fremgangsmaate for kontinuerlig fremstilling av tyggegummi.
NO953662L (no) Medisinsk plastermateriale, samt fremgangsmåte for fremstilling av materialet
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
NO911934D0 (no) Fremgangsmaate for fremstilling av bicykliske 1-aza-cykloalkaner.
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
NO944871D0 (no) Fremgangsmåte for fremstilling av polydimetylsiloksaner
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
EP0467564A3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
IL120443A (en) Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
FI941776A (fi) Menetelmä 1,2,4-tiadiatsolien valmistamiseksi
AU3187595A (en) Compounds for the treatment of restenosis
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
AU4712696A (en) The use of heterocyclic compounds
ZA97872B (en) Use of pyrolidine derivatives for the manufacture of medicaments.
ITRM950484A0 (it) Impiego dell'amtolmetineguacil (med 15) come farmaco antisecretivo sulla gastrica e quindi gastroprotettivo.
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
NO931839L (no) Fremgangsm}te for fremstilling av pergolid
AU5018893A (en) Substituted hydrindanes for the treatment of angiogenesis-dependent diseases